Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Fransson, Liselotte ^a   Dos Santos, Cristiane ^b   Wolbert, Petra ^a   Sjöholm, Åke ^a,c,d   Rafacho, Alex ^b   Ortsäter, Henrik ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c Södertälje University   (Sweden)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Beta cell; Corticosterone; Diabetes; Insulin; Islet; Liraglutide; Metabolic syndrome

Indexed keywords

EID: 84892400687     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-3     Document Type: Article

References (50)

1. Mechanisms involved in the side effects of glucocorticoids. Schacke H, Docke WD, Asadullah K, Pharmacol Ther 2002 96 23 43 10.1016/S0163-7258(02)00297- 8 12441176 (Pubitemid 35346616)
2. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV, N Engl J Med 2000 343 230 238 10.1056/NEJM200007273430401 10911004 (Pubitemid 30490390)
3. GLUT-2 function in glucose-unresponsive b cells of dexamethasone-induced diabetes in rats. Ohneda M, Johnson JH, Inman LR, Unger RH, J Clin Invest 1993 92 1950 1956 10.1172/JCI116788 8408647 (Pubitemid 23304564)
4. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Davani B, Portwood N, Bryzgalova G, Reimer MK, Heiden T, Ostenson CG, Okret S, Ahren B, Efendic S, Khan A, Diabetes 2004 53 Suppl 1 51 59 14749266
5. Increased glucocorticoid sensitivity in islet beta-cells: effects on glucose 6-phosphatase, glucose cycling and insulin release. Ling ZC, Khan A, Delauny F, Davani B, Ostenson CG, Gustafsson JA, Okret S, Landau BR, Efendic S, Diabetologia 1998 41 634 639 10.1007/s001250050961 9662043 (Pubitemid 28261396)
6. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. Lambillotte C, Gilon P, Henquin JC, J Clin Invest 1997 99 414 423 10.1172/JCI119175 9022074 (Pubitemid 27414798)
7. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, et al. Diabetes 2005 54 1090 1099 10.2337/diabetes.54.4.1090 15793248 (Pubitemid 40446323)
8. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Linssen MM, van Raalte DH, Toonen EJ, Alkema W, van der Zon GC, Dokter WH, Diamant M, Guigas B, Ouwens DM, Cell Signal 2011 23 1708 1715 10.1016/j.cellsig.2011.06.002 21689745
9. Dexamethasone counteracts the effect of prolactin on islet function: implications for islet regulation in late pregnancy. Weinhaus AJ, Bhagroo NV, Brelje TC, Sorenson RL, Endocrinology 2000 141 1384 1393 10746642 (Pubitemid 32269106)
10. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Ranta F, Avram D, Berchtold S, Dufer M, Drews G, Lang F, Ullrich S, Diabetes 2006 55 1380 1390 10.2337/db05-1220 16644695 (Pubitemid 44195377)
11. The human insulin gene contains multiple transcriptional elements that respond to glucocorticoids. Fernandez-Mejia C, Medina-Martinez O, Martinez-Perez L, Goodman PA, Pancreas 1999 18 336 341 10.1097/00006676-199905000-00002 10231837 (Pubitemid 29203305)
12. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S, Proc Natl Acad Sci U S A 1992 89 6035 6039 10.1073/pnas.89.13.6035 1631088
13. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Sadry SA, Drucker DJ, Nat Rev Endocrinol 2013 9 425 433 10.1038/nrendo.2013.47 23478327
14. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Torekov SS, Madsbad S, Holst JJ, Obes Rev 2011 12 593 601 10.1111/j.1467-789X.2011.00860.x 21401851
15. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V, J Endocrinol 1993 138 159 166 10.1677/joe.0.1380159 7852887 (Pubitemid 23266831)
16. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M, Diabetes Care 2011 34 412 417 10.2337/dc10-1677 21216851
17. Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Matsuo K, Nambu T, Matsuda Y, Kanai Y, Yonemitsu S, Muro S, Oki S, Int Med 2013 52 89 95
18. Liraglutide for the treatment of type 2 diabetes. Shyangdan D, Cummins E, Royle P, Waugh N, Health Technol Assess 2011 15 Suppl 1 77 86 21609656
19. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Montanya E, Expert Opin on Pharmacother 2012 13 1451 1467 10.1517/14656566.2012.692777
20. b-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome. Fransson L, Franzen S, Rosengren V, Wolbert P, Sjöholm Å Ortsäter H, J Endocrinol 2013 219 231 241 10.1530/JOE-13-0189 24048967
21. Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McEwen BS, Endocrinology 2010 151 2117 2127 10.1210/en.2009-1436 20211972
22. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A, Nat Protoc 2013 8 1149 1154 10.1038/nprot.2013.055 23702831
23. Increased pancreatic islet mass is accompanied by activation of the insulin receptor substrate-2/serine-threonine kinase pathway and augmented cyclin D2 protein levels in insulin-resistant rats. Rafacho A, Ribeiro DL, Boschero AC, Taboga SR, Bosqueiro JR, Int J of Exp Pathol 2008 89 264 275 10.1111/j.1365-2613.2008.00588.x (Pubitemid 352019179)
24. High doses of dexamethasone induce increased b-cell proliferation in pancreatic rat islets. Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR, Am J Physiol Endocrinol Metab 2009 296 681 689 10.1152/ajpendo.90931.2008 19158320
25. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, Willour VL, Huo Y, Rongione M, Wand GS, Potash JB, Endocrinology 2010 151 4332 4343 10.1210/en.2010-0225 20668026
26. LXRb is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, Magomedova L, Li T, Chan JF, Budd C, et al. J Clin Invest 2011 121 431 441 10.1172/JCI41681 21123945
27. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsater H, Scotney P, Nyqvist D, Samen E, Lu L, et al. Nature 2012 490 426 430 10.1038/nature11464 23023133
28. Liraglutide for weight loss in obese people. Hallberg P, Schwan S, Melhus H, Lancet 2010 375 551 author reply 552-553
29. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats. Wu L, Olverling A, Fransson L, Ortsäter H, Kappe C, Gao X, Sjöholm Å Regul Pept 2012 177 92 96 10.1016/j.regpep.2012.05.091 22587909
30. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Perry CM, Drugs 2011 71 2347 2373 10.2165/11208110-000000000-00000 22085389
31. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Larsson H, Ahren B, Diabetologia 1999 42 936 943 10.1007/s001250051251 10491753 (Pubitemid 29369601)
32. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Grill V, Pigon J, Hartling SG, Binder C, Efendic S, Metabolism 1990 39 251 258 10.1016/0026-0495(90)90043-C 2407926 (Pubitemid 20086104)
33. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H, Diabetologia 1997 40 1439 1448 10.1007/s001250050847 9447952 (Pubitemid 28004938)
34. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Besse C, Nicod N, Tappy L, Obes Res 2005 13 306 311 10.1038/oby.2005.41 15800288
35. Effects of prolonged exendin-4 administration on hypothalamic-pituitary- adrenal axis activity and water balance. Gil-Lozano M, Romani-Perez M, Outeirino-Iglesias V, Vigo E, Brubaker PL, Gonzalez-Matias LC, Mallo F, Am J Physiol Endocrinol Metab 2013 304 1105 1117 10.1152/ajpendo.00529.2012 23531615
36. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H, Int J of Obes 1983 7 529 538 (Pubitemid 14239953)
37. Lysgard madsen J, juul holst J, astrup a: the role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Verdich C, Toubro S, Buemann B, Int J Obes Relat Metab Disord 2001 25 1206 1214 10.1038/sj.ijo.0801655 11477506 (Pubitemid 32721544)
38. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. Kappe C, Patrone C, Holst JJ, Zhang Q, Sjoholm A, J of Gastroenterol 2013 48 322 332 10.1007/s00535-012-0637-5
39. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E, Action in Diabetes 5 met SUSG, Diabetologia 2009 52 2046 2055 10.1007/s00125-009-1472-y 19688338
40. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J, Liraglutide Effect Action in Diabetes-6 Study G, Diabetes Care 2010 33 1300 1303 10.2337/dc09-2260 20332351
41. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S, group L-Ss, Diabet Med 2009 26 268 278 10.1111/j.1464-5491.2009.02666.x 19317822
42. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, Group L-S, Lancet 2009 373 473 481 10.1016/S0140-6736(08)61246-5 18819705
43. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, Investigators L-S, Diabetes Care 2009 32 1224 1230 10.2337/dc08-2124 19289857
44. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR, Group L-S, Diabetes Care 2009 32 84 90 10.2337/dc08-1355 18931095
45. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, Zdravkovic M, Strauss BJ, Garber AJ, Lead, Groups L-S, Diab Obes Metab 2009 11 1163 1172 10.1111/j.1463-1326.2009.01158.x
46. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al. Diab 1993 42 1663 1672 10.2337/diab.42.11. 1663 (Pubitemid 23318125)
47. Glucocorticoids in vivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Rafacho A, Marroqui L, Taboga SR, Abrantes JL, Silveira LR, Boschero AC, Carneiro EM, Bosqueiro JR, Nadal A, Quesada I, Endocrinology 2010 151 85 95 10.1210/en.2009-0704 19880808
48. Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Rafacho A, Abrantes JL, Ribeiro DL, Paula FM, Pinto ME, Boschero AC, Bosqueiro JR, Horm Metab Res 2011 43 275 281 10.1055/s-0030-1269896 21225543
49. Effects of glucagon-like peptide-1 receptor agonists on renal function. Filippatos TD, Elisaf MS, World J of Diab 2013 4 190 201
50. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC, Diabetes 2013 62 2595 2604 10.2337/db12-1686 23524641